Clinical Trial Update: First-in-human Study of the Theranostic Pair [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G in Pancreatic Cancer [EARLY_Phase 1]

View source ↗

Summary

A first-in-human early-phase study of a theranostic pair using Ga-68 DOTA-5G and Lu-177 DOTA-ABM-5G for pancreatic cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Ga-68 DOTA-5G (68Ga-DOTA-5G)
• Lu-177 DOTA-ABM-5G (177Lu-DOTA-ABM-5G)

Snippet

Sponsor: University of California, Davis | Conditions: Metastatic Pancreatic Cancer, Locally Advanced Pancreatic Adenocarcinoma | EARLY_Phase 1 | Status: RECRUITING